Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: Subanalysis of a large-scale randomized controlled trial

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Nishimura, Rimei ^a   Nakagami, Tomoko ^b   Sone, Hirohito ^c   Ohashi, Yasuo ^d   Tajima, Naoko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cardiovascular disease (CVD); Hemoglobin A1c (HbA1c); HMG CoA reductase inhibitor; Hypercholesterolemia; MEGA Study; Pravastatin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIET; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET THERAPY; ETHNOLOGY; HOSPITALIZATION; JAPAN; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; DIET THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERCHOLESTEROLEMIA; INCIDENCE; JAPAN; LIPIDS; MALE; MIDDLE AGED; PRAVASTATIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79959635321     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-58     Document Type: Article

References (30)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Diabetic Med 1998, 15:539-553. 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S, 9686693.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000, 23:S4-S19. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
3. Ceriello A, Colagiuri S. International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabetic Med 2008, 25:1151-1156. 10.1111/j.1464-5491.2008.02565.x, 2701558, 19046192.
4. International Expert Committee International Expert Committee Report on the Role of the HbA1c Assay in the Diagnosis of Diabetes. Diabetes Care 2009, 32:1327-1334. 2699715, 19502545, International Expert Committee.
5. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
6. Blake GJ, Pradhan AD, Manson JE, Williams GR, Buring J, Ridker PM, Glynn RJ. Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med 2004, 164:757-761. 10.1001/archinte.164.7.757, 15078645.
7. Gao L, Matthews FE, Sargeant LA, Brayne C, . MRC CFAS An investigation of the population impact of variation in HbA1c levels in older people in England and Wales: from a population based multi-centre longitudinal study. BMC Public Health 2008, 8:54. 10.1186/1471-2458-8-54, 2275259, 18267013, MRC CFAS.
8. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004, 68:860-867. 10.1253/circj.68.860, 15329509, Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group.
9. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368:1155-1163. 10.1016/S0140-6736(06)69472-5, 17011942.
10. National Cholesterol Education Program Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP II) 1993, Washington, DC: US Department of Health and Human Services, National Cholesterol Education Program.
11. . Committee on Diabetes Mellitus Indices, Japan Society of Clinical Chemistry Japanese guideline for reporting HbA1c results reported in IFCC units and JDS units. Rinsho Kagaku 2008, 37:393-409. (In Japanese), Committee on Diabetes Mellitus Indices, Japan Society of Clinical Chemistry.
12. Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Okayama A, Okamura T. New diagnosis criteria for diabetes with hemoglobin HbA1c and risks of macro-vascular complications in an urban Japanese cohort: the Suita Study. Diabetes Res Clin Pract 2010, 88:e20-e23. 10.1016/j.diabres.2010.01.019, 20149470.
13. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995, 6:356-365. 10.1097/00001648-199507000-00005, 7548341.
14. Chien KL, Lin HJ, Lee BC, Hsu HC, Chen MF. Prediction model for high glycated hemoglobin concentration among ethnic Chinese in Taiwan. Cardiovasc Diabetol 2010, 9:59-67. 10.1186/1475-2840-9-59, 2955643, 20875098.
15. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
16. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117. 10.1016/0168-8227(95)01064-K, 7587918.
17. Singer E, Nathan J, Anderson SH, Wilson PW, Evans JC. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992, 41:202-208. 10.2337/diabetes.41.2.202, 1733810.
18. Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW, . Atherosclerosis Risk in Communities Study Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Care 2005, 28:1965-1973. 10.2337/diacare.28.8.1965, 16043740, Atherosclerosis Risk in Communities Study.
19. Tajima N, Kurata H, Nakaya N, Mizuno K, Ohashi Y, Kushiro T, Teramoto T, Uchiyama S, Nakamura H, . Primary Prevention Group of Adult Japanese (MEGA) Study Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Atherosclerosis 2008, 199:455-462. 10.1016/j.atherosclerosis.2008.05.027, 18635188, Primary Prevention Group of Adult Japanese (MEGA) Study.
20. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885. 10.2337/diacare.26.3.881, 12610053.
21. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, Mckillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307. 10.1056/NEJM199511163332001, 7566020.
22. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009. 10.1056/NEJM199610033351401, 8801446.
23. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
24. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, . ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158. 10.1016/S0140-6736(03)12948-0, 12686036, ASCOT Investigators.
25. Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. The Care Investigators. Circulation 1998, 98:2513-2519.
26. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696. 10.1016/S0140-6736(04)16895-5, 15325833.
27. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C, . Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. 10.1016/S0140-6736(08)60104-X, 18191683, Cholesterol Treatment Trialists' (CTT) Collaborators.
28. Kurukulasuriya LR, Sowers JR. Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovasc Diabetol 2010, 9:45-58. 10.1186/1475-2840-9-45, 2940872, 20804556.
29. Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis?. Curr Vasc Pharmacol 2010, 8:612-631. 10.2174/157016110792006879, 20507274.
30. Carson AP, Fox CS, McGuire DK, Levitan EB, Laclaustra M, Mann DM, Muntner P. Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes. Circ Cardiovasc Qual Outcomes 2010, 3:661-667. 10.1161/CIRCOUTCOMES.110.957936, 20923991.